482 assets in Prostate Cancer

Therapeutic assets addressing Prostate Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
mk-2206 Prostate Cancer	National Cancer Institute (NCI)	P2	B (57)
Ondansetron Prostate Cancer	Fred Hutchinson Cancer Center	P4	B (57)
Oxodotreotide Prostate Cancer	National Cancer Institute (NCI)	P2	B (57)
Talazoparib Prostate Cancer	M.D. Anderson Cancer Center	P3	B (57)
[68Ga]Ga-RM2 Prostate Cancer	IRCCS San Raffaele	P2	B (56)
Dasatinib Prostate Cancer	Medical University of South Carolina	P2	B (56)
Dinitrogen Monoxide Prostate Cancer	Beth Israel Deaconess Medical Center	P4	B (56)
Fosfomycin Prostate Cancer	F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica	P4	B (56)
Pegfilgrastim Prostate Cancer	Rahul Aggarwal	P2	B (56)
Pyruvate Prostate Cancer	Ivan de Kouchkovsky, MD	P2	B (56)
Rucaparib Prostate Cancer	Alliance for Clinical Trials in Oncology	P3	B (56)
Sirolimus Prostate Cancer	Medical University of South Carolina	P2/3	B (56)
Tadalafil Prostate Cancer	Surgical Outcomes Research Centre (SOuRCe)	P3	B (56)
Trastuzumab Prostate Cancer	Mayo Clinic	P2	B (56)
Vipivotide Tetraxetan Gallium Ga-68 Prostate Cancer	University of Washington	P2/3	B (56)
Atezolizumab Prostate Cancer	Exelixis	P3	CCC (55)
Ipatasertib Prostate Cancer	Hoffmann-La Roche	P2	CCC (55)
Oxycodone Prostate Cancer	Deventer Ziekenhuis	P4	CCC (55)
Pertuzumab Prostate Cancer	Mayo Clinic	P2	CCC (55)
Talogreptide Mesaroxetan Prostate Cancer	Clarity Pharmaceuticals Ltd	P2	CCC (55)
68Ga-NYM032 Prostate Cancer	Norroy Bioscience Co., LTD	P3	CCC (54)
aaa817 Prostate Cancer	Novartis Pharmaceuticals	P3	CCC (54)
Adenoviral Psa Prostate Cancer Vaccine Etbx-071 Prostate Cancer	ImmunityBio, Inc.	P2	CCC (54)
Aglatimagene Besadenovec Prostate Cancer	Candel Therapeutics, Inc.	P3	CCC (54)
Alpha Tocopherol Prostate Cancer	University of Nebraska	P3	CCC (54)
Fludeoxyglucose Prostate Cancer	University of Wisconsin, Madison	P2	CCC (54)
Gadopiclenol Prostate Cancer	Columbia University	P4	CCC (54)
INR101 Prostate Cancer	Yunhe Pharmaceutical (Tianjin) Co., Ltd	P3	CCC (54)
Oxygen Prostate Cancer	Beth Israel Deaconess Medical Center	P4	CCC (54)
Polyethylene Glycol 3350 Prostate Cancer	Chad R. Tracy	P4	CCC (54)
Psma I&T Prostate Cancer	CHU de Quebec-Universite Laval	P2	CCC (54)
Ptvg-Ar Prostate Cancer	University of Wisconsin, Madison	P2	CCC (54)
Satraplatin Prostate Cancer	Shanghai Jiao Tong University School of Medicine	P3	CCC (54)
Semaglutide Prostate Cancer	Hamilton Health Sciences Corporation	P4	CCC (54)
Sufentanyl Prostate Cancer	RenJi Hospital	P4	CCC (54)
Valaciclovir Prostate Cancer	Candel Therapeutics, Inc.	P3	CCC (54)
18f- dcfpyl Prostate Cancer	VA Greater Los Angeles Healthcare System	P2	CCC (53)
Berzosertib Prostate Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Choline C-11 Ion Prostate Cancer	Peking University Cancer Hospital & Institute	P2	CCC (53)
Darotamide Prostate Cancer	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P2	CCC (53)
Fk-Pc101 Prostate Cancer	Cellvax Therapeutics Inc	P2	CCC (53)
Formaldehyde Prostate Cancer	Hitit University	P2	CCC (53)
Golimumab Prostate Cancer	University of Washington	P2	CCC (53)
Goserelin Microspheres For Prostate Cancer	The First Affiliated Hospital of Xiamen University	P2	CCC (53)
is-002 Prostate Cancer	Intuitive Surgical	P2	CCC (53)
Isopropyl Alcohol Prostate Cancer	Hitit University	P2	CCC (53)
Ivocizumab Prostate Cancer	Fudan University	P2	CCC (53)
jsb462 Prostate Cancer	Novartis Pharmaceuticals	P2	CCC (53)
Lutetium (<Sup>177</Sup>Lu) Zadavotide Guraxetan Prostate Cancer	Jonsson Comprehensive Cancer Center	P2	CCC (53)
Memory Cytokine-Enhanced Nk Cells Prostate Cancer	ImmunityBio, Inc.	P2	CCC (53)

Showing 101 to 150 of 482 assets

PreviousPage 3 of 10Next